Analyst firms · BofA Securities · ABBV
BofA Securities ABBV price target and rating history
AbbVie Inc. (ABBV) · Health Care
BofA Securities rates AbbVie Inc. (ABBV) Buy with a $234 price target, as of its latest action on Apr 30, 2026. It has published 3 rating actions on ABBV since February 2022, including 1 upgrade and 0 downgrades. Across 7 firms with a ABBV price target in the last 12 months, the median target is $262. BofA Securities's $234 is 11% below that.
- Current rating
- Buy
- Price target
- $234
- Median target, all firms
- $262
- Actions on ABBV
- 3
BofA Securities price target on ABBV
Every BofA Securities rating on ABBV
- Apr 30, 2026
- Dec 10, 2024
- Feb 3, 2022
How other firms rate ABBV
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Erste Group | Buy | Aug 5, 2026 | |
| BofA Securities | Buy | $234 | Apr 30, 2026 |
| Canaccord Genuity | Buy | $262 | Apr 21, 2026 |
| RBC Capital Markets | Outperform | $260 | Feb 25, 2026 |
| Barclays | Overweight | $275 | Feb 20, 2026 |
| UBS | Neutral | $240 | Jan 7, 2026 |
| HSBC | Buy | $265 | Dec 10, 2025 |
Questions about BofA Securities and ABBV
- What is BofA Securities's price target for ABBV?
- BofA Securities's latest stated price target for AbbVie Inc. (ABBV) is $234, from its action on Apr 30, 2026.
- What is BofA Securities's rating on ABBV?
- BofA Securities rates ABBV Buy, a bullish rating, as of Apr 30, 2026.
- When did BofA Securities last change its view on ABBV?
- On Apr 30, 2026, BofA Securities upgrades to Buy from Neutral, price target $234.
- How does BofA Securities's ABBV target compare with other analysts?
- Across 7 firms with a ABBV price target in the last 12 months, the median target is $262. BofA Securities's $234 is 11% below that.
More ABBV rating histories
All BofA Securities ratingsABBV news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.